Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies
1
Department of Medical Oncology and Clinical Haematology, Olivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, VIC 3084, Australia
2
Bendigo Cancer Centre, Bendigo Health, Bendigo, VIC 3084, Australia
3
Department of Oncology, Northern Hospital, Melbourne, VIC 3084, Australia
4
Department of Medical Oncology, Ballarat Health Services, Ballarat, VIC 3084, Australia
5
Department of Medical Oncology, Eastern Health, Melbourne, VIC 3084, Australia
6
Eastern Health, Monash University Clinical School, Melbourne, VIC 3084, Australia
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2018, 7(4), 62; https://doi.org/10.3390/jcm7040062
Received: 31 December 2017
/
Revised: 18 February 2018
/
Accepted: 6 March 2018
/
Published: 21 March 2018
(This article belongs to the Section Hematology)
Bruton’s tyrosine kinase (BTK) is a critical terminal enzyme in the B-cell antigen receptor (BCR) pathway. BTK activation has been implicated in the pathogenesis of certain B-cell malignancies. Targeting this pathway has emerged as a novel target in B-cell malignancies, of which ibrutinib is the first-in-class agent. A few other BTK inhibitors (BTKi) are also under development (e.g., acalabrutinib). While the predominant action of BTKi is the blockade of B-cell receptor pathway within malignant B-cells, increasing the knowledge of off-target effects as well as a potential role for B-cells in proliferation of solid malignancies is expanding the indication of BTKi into non-hematological malignancies. In addition to the expansion of the role of BTKi monotherapy, combination therapy strategies utilizing ibrutinib with established regimens and combination with modern immunotherapy compounds are being explored.
View Full-Text
Keywords:
ibrutinib; Bruton’s tyrosine kinase; solid tumors
▼
Show Figures
Figure A1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
MDPI and ACS Style
Campbell, R.; Chong, G.; Hawkes, E.A. Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies. J. Clin. Med. 2018, 7, 62. https://doi.org/10.3390/jcm7040062
AMA Style
Campbell R, Chong G, Hawkes EA. Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies. Journal of Clinical Medicine. 2018; 7(4):62. https://doi.org/10.3390/jcm7040062
Chicago/Turabian StyleCampbell, Robert, Geoffrey Chong, and Eliza A. Hawkes. 2018. "Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies" Journal of Clinical Medicine 7, no. 4: 62. https://doi.org/10.3390/jcm7040062
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
